Questions about this study?
The HopeStage team will email you.
Not recruitingEUCTR 2012-003228-19
A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an ...
This historical record does not confirm current site availability.
Historical research recordMultiple countriesSchizophrenia
Understand this study
What is this study about?
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
- Listed locations
- Germany · Italy and 3 more locations
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This is historical registry information. What is the current study status and protocol?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- 1,050
- Sponsor
- EnVivo Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United Kingdom, Germany, Italy, ...
- Age range
- Not clearly listed
- Official registry ID
- EUCTR 2012-003228-19
- Official title
Show the full official title
A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of EVP-6124, an Alpha- 7 Nicotinic Acetylcholine Receptor Agonist, as an ...
Recruitment & locations
Not recruitingGermany · Italy · Poland
2 more locations
- Spain
- United Kingdom
Registry details
Historical country statuses
- Germany — Prematurely Ended
- Spain — Prematurely Ended
- United Kingdom — Completed
- Italy — Completed
- Poland — Prematurely Ended
A listed location does not confirm current availability.
Questions about this study
Who is behind this study?
The study sponsor is EnVivo Pharmaceuticals, Inc.
Is this study still recruiting?
The historical registry lists this study as not recruiting.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
2-year, Multicentre, Open-label, Flexible-dose Study to Evaluate the Safety and Tolerability of Cariprazine in the Treatment of Adolescent Patients with Schizophrenia
A 38-week, Multicenter, Randomized, Double-blind, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Mai...